Form 4: Travere Therapeutics Director Exercises Options and Sells Shares

A Travere Therapeutics director, Roy D. Baynes, exercised stock options and sold shares on January 23, 2025, according to a recent SEC filing.

Summary

• Roy D. Baynes, a director at Travere Therapeutics, exercised stock options to acquire 16,000 shares of common stock at a price of $17.50 per share on January 23, 2025.
• On the same day, Mr. Baynes sold 16,000 shares of common stock at a price of $20.00 per share.
• These transactions were executed under a pre-arranged trading plan adopted on August 16, 2024, in accordance with Rule 10b5-1(c) of the Securities Exchange Act of 1934.
• Following these transactions, Mr. Baynes directly owns 31,000 shares of Travere Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction by a company director, with no indication of positive or negative sentiment. It is a standard regulatory filing.

Industry Context

This is a routine filing related to insider trading activity, which is common for publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among corporate insiders at publicly traded companies like Travere Therapeutics, similar to practices at companies such as Amgen, Gilead Sciences, and Biogen.
• The reported transactions are typical for directors exercising stock options and selling shares, which is a regular occurrence in the biotech industry, similar to what is seen at companies like Vertex Pharmaceuticals and Regeneron Pharmaceuticals.
• The price at which the shares were sold is within the typical range for such transactions, and the difference between the exercise price and sale price is a common occurrence for stock options.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they represent a small portion of the total outstanding shares.

Key Dates

Keywords

Travere Therapeutics, insider trading, stock options, SEC Form 4, Rule 10b5-1, share sale, director transaction